The drug BMF-219 works by increasing, preserving and reactivating patients’ own healthy insulin-producing cells. Read more at ...
Philip Morris International Inc. and its subsidiary Swedish Match North America LLC are asking a Connecticut federal judge to ...
With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
A groundbreaking new drug to treat schizophrenia called Cobenfy, owned by pharmaceutical firm Bristol Myers Squibb, has been ...
In September 2024, the U.S. Food and Drug Administration (FDA) issued three guidance documents to support different clinical ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.